{"schema_version":"secwatch.filing_event.v1","accession":"0001645113-25-000003","form_type":"8-K","ticker":"NVCR","cik":"0001645113","company_name":"NovoCure Ltd","filed_at":"2025-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.289517+00:00","generated_at":"2026-05-26T02:04:47.416206+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Novocure FY2024 revenue $605M (+19%), Q4 net loss $65.9M; Optune Lua approved and launched; PANOVA-3 trial met endpoint","bullets":["FY2024 net revenues $605.2M (+19% YoY); Q4 net revenues $161.3M (+21% YoY).","Q4 net loss $65.9M ($0.61/sh); adjusted EBITDA $2.6M; cash $959.9M.","Optune Lua received FDA approval Oct 2024 for metastatic NSCLC; 52 prescriptions by year-end.","Phase 3 PANOVA-3 trial met primary endpoint in unresectable locally advanced pancreatic cancer.","2025 outlook: low mid-single digit GBM growth; margins impacted by product launches."],"urls":{"canonical":"https://secwatch.observer/filing/0001645113-25-000003","json":"https://secwatch.observer/filing/0001645113-25-000003.json","markdown":"https://secwatch.observer/filing/0001645113-25-000003.md","text":"https://secwatch.observer/filing/0001645113-25-000003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645113/000164511325000003/0001645113-25-000003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645113/000164511325000003/nvcr-20250227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T02:04:47.416206+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}